drugset / Trial / NCT06014905
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
Phase 1
Recruiting
50 enrolled
Javier Villaneuva-Meyer, MD
General Electric · collabNational Cancer Institute (NCI) · collabNational Institute for Biomedical Imaging and Bioengineering (NIBIB) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior
Timeline
- Start
- 2023-09-01
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hyperpolarized 13C-Pyruvate | Diagnostic / imaging agent | — | Intravenous |